Source: The Gateway Pundit Author: Eric A. Blair An Italian study finds that hydroxychloroquine substantially reduces the risk of death for COVID-19 patients. “We observed
Source: c19 Study A live and ongoing index of study data from around the world documenting the use of hydroxychloroquine in treatment at various stages
Source: Research Gate Conclusions Hydroxychloroquine has been shown to have consistent clinical efficacy for COVID-19 when it is used early in the outpatient setting, and
It could be possible that this treatment only works when used early and in particular patient groups with similar characteristics as in the present study.
We believe this study is fatally flawed: “Effect of hydroxychloroquine with or without azithromycin on the mortality of COVID-19 patients: a systematic review and meta-analysis”.
There seems to be a trend towards lower mortality among patients who received treatment with the combination of hydroxychloroquine and azithromycin than among those who did not
This is an Indian study about the use of hydroxychloroquine for infection prevention against COVID-19. This study has not released any official data yet.
No more as the listed studies below total 7x more patients. They consistently demonstrate that HCQ saves lives. The UK missed the boat, likely due to overdosing, and misled the world.
Hydroxychloroquine may interfere with viral infection or cytokine storms observed in Covid-19 with severe acute respiratory distress syndrome.
“We realise that chloroquine can be used in the early stage of the COVID-19 infection as prophylactic treatment. Science does not lie.”
A Belgian study has just been published, on 8,000 patients, and concludes that hydroxychloroquine reduces mortality by 30%
The study concluded that hydroxychloroquine can be effective when given early after a COVID-19 diagnosis, and there was no negative side effects.
HCQ and AZI are safe in haemodialysis patients at these doses, and HCQ concentrations were not correlated with side effects.
In this study, SARS-CoV-2 infected non-hospitalized patients hydroxychloroquine exposure was associated with a decreased rate of subsequent hospitalization.
Our study, including a large sample of patients hospitalized with COVID-19 in Italy, shows HCQ use had a 30% reduction of overall in-hospital mortality.
HCQ use was associated with a 30% lower risk of death in COVID-19 hospitalized patients. Our data doesn’t discourage use of HCQ in inpatients with COVID-19.
This Multicenter Study shows that the risk of death is 30% lower for coronavirus patients treated with hydroxychloroquine.
Source: Murray Wiseman Authors: Scholz, Derwand, Zelenko A discussion of a retrospective study early risk-stratified treatment of Covid-19 outpatients with zinc plus low-dose hydroxychloroquine and
Source: United Medical Freedom Super PAC Among our most fundamental and sacred rights is the right to medical freedom. But in the curious case of
Source: Science Direct Authors: LucyCatteauPharmD, PhDafi#NicolasDaubyMD, PhDbcdfi#MarionMontourcyMScafiEmmanuelBottieauMD, PhDefiJorisHautekietMScagfiElsGoetghebeurPhDfigSabrinavan IersselMD, PhDfihElsDuysburghMD, MPH, PhDafiHermanVan OyenMD, DrPHafhiChloéWyndham-ThomasMD, PhDafiDominiqueVan BeckhovenMD, MScafiBelgian Collaborative Group on COVID-19 hospital surveillance aEpidemiology and
Corticosteroid treatment didn’t correlate with death in our model whereas both hydroxychloroquine and azithromycin correlated with a lower mortality rate.
Source: St Vincent’s Hospital Melbourne Healthcare workers are part of the first line of defence in today’s fight against COVID-19. But as this global virus
Indeed, following bivariate analysis, hydroxychloroquine/azithromycin treatment was associated with a lower rate of ICU admission (P=0.008).
This data states that early care of COVID-19 patients at retirement homes can be effective in saving lives when treated with hydroxychloroquine.
Source: Open Letter Concerns regarding the misinterpretation of statistical hypothesis testing in clinical trials for COVID-19 This letter is an expression of concern that a
What If a person advocated that parachutes don’t work, we should ban usage and pilots who give a parachute to skydivers should lose their pilot’s license
Hydroxychloroquine for COVID patients in moderate cases within the recommendation and use criteria, is safe, highly tolerable, and with little side effects.
The 5-day course of HCQ -AZM combination did not lead to significant QT prolongation and other conduction delays compared to baseline ECG in non-ICU COVID19(+) patients.
They should be embarrassed but they really need to be held accountable. Physicians have a responsibility to act in the best interests of their patients.
In rheumatological conditions hydroxychloroquine has actually been shown to reduce the risk of heart arrhythmias.
Source: France Soir An Italian study carried out on a group of more than 3,000 patients, hospitalized for Covid-19, concluded that “the use of hydroxycholoroquine
HCQ treatment can reduce systemic inflammation and inhibit the cytokine storm, thus protecting multiple organs from inflammatory injuries.
Source: Springer Link Dear Editor, The coronavirus disease 2019 (COVID-19) pandemic caused by widespread infection with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Chen
The evidence shown in this work let us think that Zn(II) indeed may play a role in the viral cell cycle, and zinc ionophores boost zinc’s effects.
Source: Newsmax An Italian study found that hospitalized coronavirus patients who took anti-malaria drug hydroxychloroquine combined with azithromycin were 66% less likely to die. Science Direct reports that
Indeed, our study suggests that AZI±HCQ might have impacted COVID-19 outcome in a population of patients, optimal timing of treatment interventions to study
The metabolic inhibitors determine which pathways actively inhibits mitochondrial ATP production with hydroxychloroquine
Source: The Gateway Pundit How many tens of thousands of Americans must die because of Dr. Fauci’s mistakes? It is becoming more and more apparent
Under ‘Time to resolution of symptoms’ in this article’s interactive diagram, it states that out of the studies referenced, “Hydroxychloroquine might be the most effective in
hydroxycholoroquine + azithromycin was associated with a 66% reduction in risk of death as compared to controls; the analysis also suggested a larger effectiveness of hydroxychloroquine in patients with less severe COVID-19 disease
